Loading...
•
Sep 30, 2025
Globus Medical Q3 2025 Earnings Report
Globus Medical delivered strong Q3 2025 results, highlighted by 23% revenue growth and improved profitability from synergies and operational execution.
Key Takeaways
Globus Medical reported Q3 2025 revenue of $769.0 million, driven by strength in the U.S. Spine business and contributions from Nevro. GAAP net income more than doubled year-over-year, and adjusted EBITDA and free cash flow reached record levels.
Revenue reached $769.0 million, up 22.9% year-over-year.
GAAP net income grew to $119.0 million, up 129.5%.
Non-GAAP EPS was $1.18, a 42.6% increase from Q3 2024.
Free cash flow totaled $213.9 million, a record high for the company.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Globus Medical raised its full-year 2025 revenue and earnings guidance, expecting strong momentum from organic growth and Nevro integration.
Positive Outlook
- Revenue guidance raised to $2.86–$2.90 billion.
- Non-GAAP EPS guidance raised to $3.75–$3.85.
- Nevro acquisition expected to be accretive in 2025.
- Strong operational leverage from NuVasive and Nevro integrations.
- Continued strength in U.S. Spine and base business performance.
Challenges Ahead
- Enabling Technologies revenue declined year-over-year.
- International revenue growth impacted by currency fluctuations.
- Increased restructuring and integration-related costs.
- Inventory levels rose significantly versus prior year.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...